AAAAAA

   
Results: 1-20 |
Results: 20
PROGNOSTIC VALUE OF FAS RECEPTOR AND RB PROTEIN EXPRESSION IN PATIENTS WITH ESOPHAGEAL ADENO-CARCINOMA ARISING IN BARRETTS METAPLASIA
Authors: COPPOLA D MORA L SCHREIBER R DALTON W KARL RC
Citation: D. Coppola et al., PROGNOSTIC VALUE OF FAS RECEPTOR AND RB PROTEIN EXPRESSION IN PATIENTS WITH ESOPHAGEAL ADENO-CARCINOMA ARISING IN BARRETTS METAPLASIA, Gastroenterology, 114(4), 1998, pp. 49-49
EXPRESSION OF THE HUMAN NRAMP1 GENE IN PROFESSIONAL PRIMARY PHAGOCYTES - STUDIES IN BLOOD-CELLS AND IN HL-60 PROMYELOCYTIC LEUKEMIA
Authors: CELLIER M SHUSTIK C DALTON W RICH E HU JX MALO D SCHURR E GROS P
Citation: M. Cellier et al., EXPRESSION OF THE HUMAN NRAMP1 GENE IN PROFESSIONAL PRIMARY PHAGOCYTES - STUDIES IN BLOOD-CELLS AND IN HL-60 PROMYELOCYTIC LEUKEMIA, Journal of leukocyte biology, 61(1), 1997, pp. 96-105
DONOR LEUKOCYTE INFUSIONS IN 140 PATIENTS WITH RELAPSED MALIGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: COLLINS RH SHPILBERG O DROBYSKI WR PORTER DL GIRALT S CHAMPLIN R GOODMAN SA WOLFF SN HU W VERFAILLIE C LIST A DALTON W OGNOSKIE N CHETRIT A ANTIN JH NEMUNAITIS J
Citation: Rh. Collins et al., DONOR LEUKOCYTE INFUSIONS IN 140 PATIENTS WITH RELAPSED MALIGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Journal of clinical oncology, 15(2), 1997, pp. 433-444
A PHASE-III STUDY EVALUATING CD34(-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR PATIENTS WITH ADVANCED MULTIPLE-MYELOMA - ENGRAFTMENT RESULTS() SELECTED VERSUS UNSELECTED AUTOLOGOUS PERIPHERAL)
Authors: SCHILLER G STEWART AK BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANFOLO S STIFF P PINEIRO L DALTON W HO A VESCIO R BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: G. Schiller et al., A PHASE-III STUDY EVALUATING CD34(-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR PATIENTS WITH ADVANCED MULTIPLE-MYELOMA - ENGRAFTMENT RESULTS() SELECTED VERSUS UNSELECTED AUTOLOGOUS PERIPHERAL), Blood, 90(10), 1997, pp. 960-960
MYELOMA CELL TUMOR REDUCTION IN PBPC AUTOGRAFTS FOLLOWING CD34 SELECTION - THE RESULTS OF A PHASE-III TRIAL USING THE CEPRATE DEVICE
Authors: VESCIO R STEWART A BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANTOLO S STIFF P PINERO L DALTON W HO A SCHILLER G BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: R. Vescio et al., MYELOMA CELL TUMOR REDUCTION IN PBPC AUTOGRAFTS FOLLOWING CD34 SELECTION - THE RESULTS OF A PHASE-III TRIAL USING THE CEPRATE DEVICE, Blood, 90(10), 1997, pp. 1872-1872
INCREASE IN CIRCULATING TUMOR-CELL BURDEN DURING MOBILIZATION CHEMOTHERAPY PREDICTS FOR RELAPSE AFTER AUTOLOGOUS TRANSPLANTATION IN MULTIPLE-MYELOMA PATIENTS
Authors: VESCIO R STEWART A BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANTOLO S STIFF P PINERO L DALTON W HO A SCHILLER G BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: R. Vescio et al., INCREASE IN CIRCULATING TUMOR-CELL BURDEN DURING MOBILIZATION CHEMOTHERAPY PREDICTS FOR RELAPSE AFTER AUTOLOGOUS TRANSPLANTATION IN MULTIPLE-MYELOMA PATIENTS, Blood, 90(10), 1997, pp. 2515-2515
THE DETECTION OF KSHV IS INCREASED BY MOBILIZATION CHEMOTHERAPY AND REDUCED IN AUTOGRAFTS BY CD34-SELECTION
Authors: VESCIO R WU C RETTIG M STEWART A BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANTOLO S STIFF P PINERO L DALTON W HO A SCHILLER G BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: R. Vescio et al., THE DETECTION OF KSHV IS INCREASED BY MOBILIZATION CHEMOTHERAPY AND REDUCED IN AUTOGRAFTS BY CD34-SELECTION, Blood, 90(10), 1997, pp. 2516-2516
FUNCTIONAL INTERACTIONS BETWEEN SYNTHETIC ALKYL PHOSPHOLIPDS AND THE ABC TRANSPORTERS P-GLYCOPROTEIN, STE-6, MRP, AND PGH-1
Authors: RUETZ S BRAULT M DALTON W GROS P
Citation: S. Ruetz et al., FUNCTIONAL INTERACTIONS BETWEEN SYNTHETIC ALKYL PHOSPHOLIPDS AND THE ABC TRANSPORTERS P-GLYCOPROTEIN, STE-6, MRP, AND PGH-1, Biochemistry, 36(26), 1997, pp. 8180-8188
MODULATION OF ANTHRACYCLINE RESISTANCE IN POOR-RISK ACUTE MYELOID-LEUKEMIA (AML) WITH SDZ PSC-833 - RESULTS OF A PHASE I II MULTICENTER STUDY/
Authors: LIST AF KARANES C DORR R SPIER C GROGAN T GREER J MOORE J WEINBERGER J SCHILLER G DALTON W PEARCE T LITCHMAN M
Citation: Af. List et al., MODULATION OF ANTHRACYCLINE RESISTANCE IN POOR-RISK ACUTE MYELOID-LEUKEMIA (AML) WITH SDZ PSC-833 - RESULTS OF A PHASE I II MULTICENTER STUDY/, Blood, 88(10), 1996, pp. 1156-1156
PHASE-I STUDY OF THE CHEMOSENSITIZER SDZ PSC-833 IN COMBINATION WITH VAD CHEMOTHERAPY TO REVERSE MULTIDRUG-RESISTANCE
Authors: DALTON W GREIPP P GREENBERG P STIFF P BALLESTER O FRIEDENBERG W SALMON S KYLE R CHARNICK S PEARCE T
Citation: W. Dalton et al., PHASE-I STUDY OF THE CHEMOSENSITIZER SDZ PSC-833 IN COMBINATION WITH VAD CHEMOTHERAPY TO REVERSE MULTIDRUG-RESISTANCE, Blood, 88(10), 1996, pp. 2638-2638
PHASE-III RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RHGM-CSF FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: NEMUNAITIS J ROSENFELD CS ASH R FREEDMAN MH DEEG HJ APPELBAUM F SINGER JW FLOMENBERG N DALTON W ELFENBEIN GJ RIFKIN R RUBIN A AGOSTI J HAYES FA HOLCENBERG J SHADDUCK RK
Citation: J. Nemunaitis et al., PHASE-III RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RHGM-CSF FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 15(6), 1995, pp. 949-954
NRAMP1 SPECIFIC EXPRESSION IN PROFESSIONAL PHAGOCYTES
Authors: CELLIER M KLIMECKI W BUU N RICH E SCHURR E DALTON W SHUSTIK C GROS P
Citation: M. Cellier et al., NRAMP1 SPECIFIC EXPRESSION IN PROFESSIONAL PHAGOCYTES, Blood, 86(10), 1995, pp. 1998-1998
EFFECTS OF COMBINED ANTIGROWTH FACTOR-RECEPTOR TREATMENT ON IN-VITRO GROWTH OF MULTIPLE-MYELOMA
Authors: TAETLE R DOSSANTOS B OHSUGI Y KOISHIHARA Y YAMADA Y MESNER H DALTON W
Citation: R. Taetle et al., EFFECTS OF COMBINED ANTIGROWTH FACTOR-RECEPTOR TREATMENT ON IN-VITRO GROWTH OF MULTIPLE-MYELOMA, Journal of the National Cancer Institute, 86(6), 1994, pp. 450-455
PROSPECTIVE MULTICENTER TRIAL OF DONOR BUFFY COAT INFUSION FOR RELAPSED HEMATOLOGIC MALIGNANCY POST-ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
Authors: COLLINS R WOLFF S LIST A CHRISTIANSEN N PINEIRO L GREER J GOODMAN S DALTON W GONZALEZ G HERZIG G PHILLIPS G FAY J
Citation: R. Collins et al., PROSPECTIVE MULTICENTER TRIAL OF DONOR BUFFY COAT INFUSION FOR RELAPSED HEMATOLOGIC MALIGNANCY POST-ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 84(10), 1994, pp. 10000333-10000333
CLONAL CHROMOSOME-ABNORMALITIES IN HUMAN BREAST CARCINOMAS .1. 28 CASES WITH PRIMARY DISEASE
Authors: THOMPSON F EMERSON J DALTON W YANG JM MCGEE D VILLAR H KNOX S MASSEY K WEINSTEIN R BHATTACHARYYA A TRENT J
Citation: F. Thompson et al., CLONAL CHROMOSOME-ABNORMALITIES IN HUMAN BREAST CARCINOMAS .1. 28 CASES WITH PRIMARY DISEASE, Genes, chromosomes & cancer, 7(4), 1993, pp. 185-193
CLONAL CHROMOSOME-ABNORMALITIES IN HUMAN BREAST CARCINOMAS .2. 34 CASES WITH METASTATIC DISEASE
Authors: TRENT J YANG JM EMERSON J DALTON W MCGEE D MASSEY K THOMPSON F VILLAR H
Citation: J. Trent et al., CLONAL CHROMOSOME-ABNORMALITIES IN HUMAN BREAST CARCINOMAS .2. 34 CASES WITH METASTATIC DISEASE, Genes, chromosomes & cancer, 7(4), 1993, pp. 194-203
PHASE-I II TRIAL OF CYCLOSPORINE AS A CHEMOTHERAPY-RESISTANCE MODIFIER IN ACUTE-LEUKEMIA/
Authors: LIST AF SPIER C GREER J WOLFF S HUTTER J DORR R SALMON S FUTSCHER B BAIER M DALTON W
Citation: Af. List et al., PHASE-I II TRIAL OF CYCLOSPORINE AS A CHEMOTHERAPY-RESISTANCE MODIFIER IN ACUTE-LEUKEMIA/, Journal of clinical oncology, 11(9), 1993, pp. 1652-1660
REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY
Authors: LEYLANDJONES B DALTON W FISHER GA SIKIC BI
Citation: B. Leylandjones et al., REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY, Cancer, 72(11), 1993, pp. 3484-3488
EXPRESSION AND FUNCTION OF P-GLYCOPROTEIN MDRL (P-GP) IN NORMAL PERIPHERAL-BLOOD LEUKOCYTES/
Authors: KLIMECKI W FUTSCHER B GROGAN T DALTON W
Citation: W. Klimecki et al., EXPRESSION AND FUNCTION OF P-GLYCOPROTEIN MDRL (P-GP) IN NORMAL PERIPHERAL-BLOOD LEUKOCYTES/, Blood, 82(10), 1993, pp. 10000238-10000238
PHASE-III DOUBLE-BLIND TRIAL OF RHGM-CSF (SARGRAMOSTIN) FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANT (BMT)
Authors: NEMUNAITIS J ROSENFELD C ASH R FLOMENBERG N FRIEDMAN M DEEG J APPELBAUM F SINGER JW DALTON W ELFENBEIN G RIFKIN R RUBIN A AGOSTI J HAYES FA SHADDUCK RK
Citation: J. Nemunaitis et al., PHASE-III DOUBLE-BLIND TRIAL OF RHGM-CSF (SARGRAMOSTIN) FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANT (BMT), Blood, 82(10), 1993, pp. 10000286-10000286
Risultati: 1-20 |